Department of Medical Biosciences, Pathology, Translational Research Center (TRC), Umeå Universitet, Umeå, Väasterbotten, Sweden
Department of Medical Biosciences, Pathology, Translational Research Center (TRC), Umeå Universitet, Umeå, Väasterbotten, Sweden.
J Clin Pathol. 2021 Apr;74(4):216-222. doi: 10.1136/jclinpath-2020-206693. Epub 2020 May 28.
Renal cell carcinoma (RCC) includes diverse tumour types characterised by various genetic abnormalities. The genetic changes, like mutations, deletions and epigenetic alterations, play a crucial role in the modification of signalling networks, tumour pathogenesis and prognosis. The most prevalent RCC type, clear cell RCC (ccRCC), is asymptomatic in the early stages and has a poorer prognosis compared with the papillary and the chromophobe types RCCs. Generally, ccRCC is refractory to chemotherapy and radiation therapy. Loss of von Hippel-Lindau (VHL) gene and upregulation of hypoxia-inducible factors (HIF), the signature of most sporadic ccRCC, promote multiple growth factors. Hence, VHL/HIF and a variety of pathways, including phosphatase and TEnsin homolog on chromosome 10/phosphatidylinositol-3-kinase (PI3K)/AKT, are closely connected and contribute to the ontogeny of ccRCC. In the recent decade, multiple targeting agents have been developed based on blocking major signalling pathways directly or indirectly involved in ccRCC tumour progression, metastasis, angiogenesis and survival. However, most of these drugs have limitations; either metastatic ccRCC develops resistance to these agents, or despite blocking receptors, tumour cells use alternate signalling pathways. This review compiles the state of knowledge about the PI3K/AKT signalling pathway confined to ccRCC and its cross-talks with VHL/HIF pathway.
肾细胞癌(RCC)包括多种肿瘤类型,其特征是具有各种遗传异常。遗传变化,如突变、缺失和表观遗传改变,在信号网络的修饰、肿瘤发病机制和预后中起着关键作用。最常见的 RCC 类型,透明细胞 RCC(ccRCC),在早期阶段无症状,与乳头状和嫌色性 RCC 相比预后较差。一般来说,ccRCC 对化疗和放疗有抗性。von Hippel-Lindau(VHL)基因的缺失和缺氧诱导因子(HIF)的上调,是大多数散发性 ccRCC 的特征,促进了多种生长因子的产生。因此,VHL/HIF 和多种途径,包括 10 号染色体上的磷酸酶和张力蛋白同源物/磷脂酰肌醇-3-激酶(PI3K)/蛋白激酶 B(AKT),密切相关,有助于 ccRCC 的发生。在过去的十年中,已经开发出多种靶向药物,这些药物基于直接或间接地阻断涉及 ccRCC 肿瘤进展、转移、血管生成和存活的主要信号通路。然而,这些药物中的大多数都有局限性;要么转移性 ccRCC 对这些药物产生耐药性,要么尽管阻断了受体,肿瘤细胞仍会使用替代信号通路。这篇综述总结了关于 PI3K/AKT 信号通路在 ccRCC 中的知识状况及其与 VHL/HIF 通路的交叉对话。